AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Protein-serine O-palmitoleoyltransferase porcupine

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9H237

UPID:

PORCN_HUMAN

Alternative names:

Protein MG61

Alternative UPACC:

Q9H237; B2RBN8; B7ZAR3; Q14829; Q9H234; Q9H235; Q9H236; Q9UJU7

Background:

Protein-serine O-palmitoleoyltransferase porcupine, also known as Protein MG61, plays a pivotal role in the Wnt signaling pathway. It facilitates the attachment of palmitoleate, a specific fatty acid, to Wnt proteins, which is crucial for their interaction with frizzled receptors.

Therapeutic significance:

Given its central role in the Wnt signaling pathway, which is implicated in Focal dermal hypoplasia, understanding the function of Protein-serine O-palmitoleoyltransferase porcupine could pave the way for novel therapeutic approaches for this and potentially other related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.